Agoracom Blog

Red Light Holland $TRIP.ca $TRUFF Red Light Holland’s iMicro Digital Care App Launches Virtual Telecounseling $RVV.ca $PSYC $FTRP $BUZZ

Posted by AGORACOM at 10:03 AM on Wednesday, March 3rd, 2021
https://i.ibb.co/ZdKv64V/Red-Light-Holland-Square.jpg

Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTC Pink: TRUFF) (“Red Light Holland” or the “Company”) is pleased to announce the launch of its Virtual Telecounseling membership program on the Company’s iMicrodose Digital Care App in the Netherlands. The app currently in use by consumers, is accessible from phones, tablets or computers. The telecounseling membership program will be seamlessly integrated into the privacy first iMicro Digital Care web app creating a new frontier for virtual psychedelic platforms. Online support will be offered to adults exploring microdosing with iMicrodose packs powered by Red Light Holland in the Netherlands. Members will be able to approve and share their iMicro Digital Care app data and connect with Red Light Holland’s certified therapist and microdosing expert, Jeff Hamburg, who will provide live virtual telecounseling. Adults can now register to the membership program by going to www.iMicrodose.nl.

“Red Light Holland is extremely proud to introduce virtual telecounseling, the use of digital information and communication technologies to help support the microdosing community. This is just another example of how we are promoting responsible use of our iMicrodose packs. This membership program will bring expert knowledge to the people in the Netherlands,” said Red Light Holland CEO and Director, Todd Shapiro. “I’m excited to have an experienced counselor like Jeff Hamburg connect with Red Light Holland consumers via telecounseling facilitating growth and wellbeing.”

“It’s thrilling to work with Red Light Holland, a company that is immediately building support structures for their customers. I’m excited to be able to offer my experience and knowledge on their consumer’s microdosing journey virtually through telecounseling on the iMicro Digital Care app,” said therapist and microdosing expert Jeff Hamburg.

The company will be offering two tiers of 3 month memberships:

(i) Growth Membership, priced at 75 euro: Includes bi-monthly online support group sessions led by Jeff Hamburg, textual consultation through the iMicro app, a monthly microdosing and creativity event as well as discounts and unique benefits for purchasing Red Light Holland merchandise.

(ii) Transform Membership, currently priced at a rate of 225 euro: For those who are interested in more personal one on one counseling with Jeff Hamburg. The transform membership will include 5 hour private sessions along with all benefits of the Growth membership.

Jeff Hamburg will also be offering short consultations for adults in the Netherlands curious to learn more about microdosing. Adults can register to the membership program or book a free consultation by going to www.iMicrodose.nl.

Read More: https://agoracom.com/ir/RedLightHolland/forums/discussion/topics/756476-red-light-holland-s-imicro-digital-care-app-launches-virtual-telecounseling/messages/2306221#message

Royal Helium $RHC.ca Announces Production Testing Underway at Climax-1 and Climax-2 $DME.ca $APD $AHELF

Posted by AGORACOM at 9:58 AM on Wednesday, March 3rd, 2021

Royal Helium Ltd. (“Royal” or the “Company”) (TSXV: RHC) announces that it has engaged two service rigs and that the completions and testing program has been initiated at Climax-1 and Climax-2.  The finalized testing program, which was developed in concert with Sproul Associates Ltd., involves the sequential perforation and gas flow testing of several separate intervals identified during drilling.  Finalized results from the testing program will be reported as the information becomes available.

Royal further announces that the Climax-3 helium well has been drilled to its target depth of 2,600 metres.  Royal’s completion team is reviewing the log data at Climax-3 to determine the intervals to be production tested. The completion and testing program at Climax-3 will commence once testing is complete on Climax-2. 

Andrew Davidson, President and CEO of Royal comments, “We are pleased to have our initial 3 wells at Climax drilled to target depth and we are excited to be production testing these high value targets. We want to thank the team from Savanna 419 for their diligent work in completing this drilling program safely and effectively”. 

Mr. Davidson continues “With 2 service rigs operating we anticipate the testing to be completed on all 3 wells over the next few weeks. While any significant developments will be announced as they are received, all results will be evaluated by Sproule for a potential helium resource and production over multiple separate zones within this large structural closure”.

The three Climax wells were drilled into the Precambrian basement, directly below the Deadwood Formation. The Deadwood is a sand and shale sequence that is a known helium production zone in Saskatchewan. These first three wells are targeting different parts of the same large structural trap identified on the central portion of the Climax land block.

Read More: https://agoracom.com/ir/RoyalHelium/forums/discussion/topics/756474-royal-helium-announces-production-testing-underway-at-climax-1-and-climax-2/messages/2306214#message

Mountain Valley MD $MVMD $MVMDF Proceeding with FDA Pathway Application for Novel Ivectosol™ $CTLT $MRNA $NVAX

Posted by AGORACOM at 9:54 AM on Wednesday, March 3rd, 2021
This image has an empty alt attribute; its file name is MVMD-Small.png

Mountain Valley MD Holdings Inc. (the “Company” or “MVMD“) (CSE: MVMD) (FRA: 20MP) (OTCQB: MVMDF) is pleased to announce it has contracted Camargo Pharmaceutical Services, LLC (“Camargo”) to provide regulatory consulting services to support MVMD’s pursuit of U.S. Food and Drug Administration (FDA) approval of its novel Ivectosol™ rapid dissolve oral format.

Camargo is recognized as one of the most experienced global organizations who specialize in drug and combination device product development and approval utilizing the regulatory pathway provided for in Section 505(b)(2) of the US Federal Food, Drug, and Cosmetic Act.  Over the last decade, Camargo has established a leading track record with 505(b)(2) investigational new drug (“IND”) and new drug applications (“NDA” preparations and submissions, including participation in more than 1100 Agency meetings and more than 200 FDA NDA and ANDA (Abbreviated New Drug Applications) approvals.

“After successful pre-clinical studies of our novel solubilized Ivectosol™ sublingual in our pre-clinical trials, this is a critical next step in the approval process to support our human application objectives,” stated Mike Farber, Director of Life Sciences at Mountain Valley MD.   “Camargo will be a great partner to accelerate our efforts for the initial pre-IND presentation to the FDA outlining Ivermectin’s prior usage history and extensive safety record for the FDA’s assessment and approval pathway.”

The 505(b)(2) new drug application is one of three U.S. Food and Drug Administration drug approval pathways and represents an appealing regulatory strategy by way of helping to avoid unnecessary duplication of studies already performed on a previously approved drug.  The Company believes the 505(b)(2) pathway will result in a much less expensive and much faster route to approval, compared with a traditional development pathway, while creating a new, differentiated Ivermectin product with tremendous commercial value.

“Camargo is proud to partner with Mountain Valley MD to advance their novel solubilized Ivermectin sublingual wafer,” said Catherine Gatza, PhD, Vice President, Regulatory and Strategy at Camargo. “This program delivers important advantages to the parasitic infection treatment landscape by providing an alternative dosage form.”

As previously communicated, MVMD’s solubility technology applied to the Ivermectin drug is the only form in the world that uses strictly excipients that are currently approved by the US Food and Drug Administration (FDA), making it a leading candidate for human injection and sublingual applications as well as significantly broader husbandry and companion animal treatments based on its low viscosity.

“The U.S. FDA approval would prove the efficacy and safety of MVMD’s Ivectosol™ wafer at one of the highest standards in the world and would assist in facilitating greater access to key global markets in an accelerated capacity,” stated Dennis Hancock, President & CEO of Mountain Valley MD.  “The human approval pathway timed with our aggressive pursuit of husbandry applications, is core to making our Ivectosol™ products the number one commercial form of Ivermectin in the world.”

Read More: https://agoracom.com/ir/MountainValleyMD/forums/discussion/topics/756473-mountain-valley-md-proceeding-with-fda-505-b-2-pathway-application-for-novel-ivectosol/messages/2306213#message

ImagineAR $IP.ca $IPNFF Awarded US Patent Focused on Location-Based Virtual Gameplay $DBO.ca $YDX.ca $SEV.ca $NTAR.ca

Posted by AGORACOM-JC at 9:08 AM on Wednesday, March 3rd, 2021
http://www.smallcapepicenter.com/imagine%20ar%20squre.jpg
  • Announced it has been awarded patent number US10,946,284 by the United States Patent and Trademark Office (USPTO).
  • The patent, titled “Systems and Methods for Capture and Use of Local Elements in Gameplay,” adds to ImagineAR’s deep intellectual property portfolio and is focused on location-based virtual gameplay.
  • Patent was developed with a focus on creating a rich multi-player gaming experience where aspects of gameplay may change based on the geographic location of other players as they join and leave the game.

VANCOUVER , BC and ERIE, Pa. , March 3, 2021 /- ImagineAR (CSE: IP) (OTCQB: IPNFF) an Augmented Reality company that enables sports teams, entertainers, brands and businesses to instantly create immersive global mobile phone AR campaigns, is proud to announce it has been awarded patent number US10,946,284 by the United States Patent and Trademark Office (USPTO). The patent, titled “Systems and Methods for Capture and Use of Local Elements in Gameplay,” adds to ImagineAR’s deep intellectual property portfolio and is focused on location-based virtual gameplay.

The patent was developed with a focus on creating a rich multi-player gaming experience where aspects of gameplay may change based on the geographic location of other players as they join and leave the game. The invention can utilize mobile devices with location sensing capabilities, such as GPS.

ImagineAR CEO, Alen Paul Silverrstieen, stated “This newly approved US patent, in addition to our existing portfolio of five patents, further demonstrates the advanced technology and market leadership of ImagineAR in the North American Augmented Reality marketplace.”

ImagineAR was represented before the USPTO by White and Williams LLP attorney Frank Bruno .

Read More: https://agoracom.com/ir/Imaginear/forums/discussion/topics/756465-imaginear-otcqb-ipnff-awarded-us-patent-focused-on-location-based-virtual-gameplay/messages/2306201#message

Blockchain Foundry $BCFN.ca DeFi Strategy, Enterprise Development Initiatives and New Customer Acquisitions $HUT.ca $BITF.ca $GLXY.ca $HIVE.ca $VYGR.ca

Posted by AGORACOM-JC at 9:00 AM on Wednesday, March 3rd, 2021
http://blog.agoracom.com/wp-content/uploads/2020/10/blockchain-foundry-square.png
  • Company is actively pursuing a two-pronged strategy to roll out products in the decentralized finance (“DeFi”) space and more traditional enterprise software solutions which leverage blockchain capabilities.
  • DeFi is a new area of blockchain technology that uses smart contracts to perform operations that would typically be performed by centralized entities or a series of intermediaries.
  • BCF has been actively evaluating blockchain-enabled product opportunities in several industry verticals, including remittances, loyalty applications and digital identities.

TORONTO, March 03, 2021 — Blockchain Foundry Inc. (“BCF” or the “Company”) (CSE:BCFN), a leading North American blockchain development firm, is pleased to provide an update on its product strategy, development initiatives and new customer acquisitions.

Product Strategy

The Company is actively pursuing a two-pronged strategy to roll out products in the decentralized finance (“DeFi”) space and more traditional enterprise software solutions which leverage blockchain capabilities.

Decentralized Finance (DeFi) Initiatives

DeFi is a new area of blockchain technology that uses smart contracts to perform operations that would typically be performed by centralized entities or a series of intermediaries. Some examples of DeFi applications include:

  • Non-fungible tokens (“NFTs”), representing unique items such as works of art, digital collectibles or in-game items;
  • Automatic trading, market making and liquidity pools for digital assets;
  • Insurance contracts triggered automatically by pre-specified events and conditions; and
  • Stablecoins which are pegged to fiat currencies, precious metals or other traditional asset classes.

Most DeFi applications are built on the Ethereum blockchain. As discussed in previous Company disclosure, BCF has been a major contributor to the open source Syscoin blockchain protocol, which has cost, speed, security and scalability advantages over many public blockchains, including Ethereum.

BCF is assisting with the development efforts for the next release of Syscoin, version 4.2, which is expected to be released by April 30, 2021. Syscoin 4.2 will feature support for NFTs, a commonly requested feature by BCF clients, and will lay the groundwork for future Syscoin innovations, including Syscoin’s Network-Enhanced Virtual Machine (“NEVM”). NEVM is an improved version of Ethereum’s Virtual Machine (“EVM”) and serves as the backbone for smart-contract execution within the Syscoin ecosystem. NEVM will provide better security, speed and scalability through the use of zero-knowledge proofs (“ZKPs”) 1 .

Key to the Company’s strategy is enhancing the Syscoin protocol in ways which allow BCF to operate decentralized finance applications in much more efficient ways than are currently possible on today’s public blockchains. Over the next 3-6 months, the Company intends to release an initial DeFi solution to be developed on Ethereum or Binance Smart Chain. This initial DeFi implementation is expected to have lower fees than competing products due to the Company’s unique expertise in ZKPs in combination with Layer 1 and 2 systems which will be adapted to this solution. Competing DeFi products, most notably products like Uniswap, Balancer, Kyberswap and 1Inch, charge a fee based on the transactional volume processed by the platform. Uniswap charges a fee of 0.3% and frequently handles more than $1 billion in daily trading volume and processes over 100,000 daily transactions 2 . On the current Ethereum network, 100,000 transactions would cost approximately $300K compared with less than $1 for the same number of transactions on the Syscoin network 3 .

Many DeFi applications are difficult to use, prone to scams and fraud and generally do not appeal to mainstream users. BCF intends to leverage its expertise in developing consumer and enterprise solutions for clients to distinguish its offering from others on the market and appeal to a mainstream audience.

BCF’s initial DeFi release will be deployed, tested and improved upon throughout 2021 with the intention of releasing a more scalable, faster and cheaper implementation on Syscoin as soon as the underlying Syscoin architecture is ready for deployment, currently estimated for Q4 2021 or Q1 2022.

Enterprise Development Initiatives

BCF has been actively evaluating blockchain-enabled product opportunities in several industry verticals, including remittances, loyalty applications and digital identities. For each use case, the Company has been engaging with potential industry partners who would be the initial users of any products developed by BCF and who would assist the Company in its roll out of these products to enterprise users. The Company continues to evaluate enterprise use cases and partnerships and will provide updates to the market as these initiatives progress.

New Customer Acquisition

In addition to its product development strategy, the Company continues to provide consulting and development services to projects where it believes it has a strong technological advantage and can add value for its clients.

BCF has recently engaged in two solution design projects, one for a carbon exchange product using a digital asset to represent sequestered carbon, and another project building an NFT platform to track the popularity of music, movies and TV shows and produce a corresponding payout. Both of these projects represent innovative use cases for blockchain technology and BCF looks forward to completing these solution designs and beginning work on full scale design and implementation proposals for these clients.

Novamind $NM.ca $NVMDF Expands Leadership Team, Accelerating M&A $RVV.ca $MMED $PSYC.ca $FTRP.ca $CMPS $NUMI.ca

Posted by AGORACOM-JC at 8:52 AM on Wednesday, March 3rd, 2021
  • Announced the appointment of Joseph Braganza to the role of Senior Vice President, Head of M&A.
  • Mr. Braganza joins the senior leadership team with a mandate to lead Novamind’s M&A strategy, accelerating the Company’s expansion plans for its network of clinics, retreats and clinical research sites.

TORONTO, ON / March 3, 2021 / Novamind Inc.,(CSE:NM)(OTC PINK:NVMDF) (“Novamind” or the “Company”), a leading mental health company specialized in psychedelic medicine, announces the appointment of Joseph Braganza to the role of Senior Vice President, Head of M&A. Mr. Braganza joins the senior leadership team with a mandate to lead Novamind’s M&A strategy, accelerating the Company’s expansion plans for its network of clinics, retreats and clinical research sites.

Joseph has gained tenure as a M&A specialist and strategist, building sustainable programmatic M&A approaches for high-growth organizations. Leveraging over 20 years of professional experience, Joseph recently led the M&A group as Vice President, Business and Corporate Development at Canadian Addiction Treatment Centres (CATC), a consolidator of outpatient addiction treatment clinics that currently operates over 70 clinics and an inpatient residential treatment facility. Joseph previously held senior M&A roles at People Corp. (acquired by Goldman Sachs Merchant Banking), Rexall Health Solutions (a subsidiary of McKesson Corp.) and Deloitte.

“I am deeply committed to Novamind’s vision to scale their operating model for psychedelic medicine,” Braganza commented. “Facilitating greater access to these breakthrough treatments is critical in helping people find new ways to improve their mental health. I look forward to working with the leadership team as we pursue Novamind’s vision.”

Yaron Conforti, CEO and Director of Novamind added, “We’re excited to announce Joseph’s appointment to lead our M&A team. Joseph’s experience acquiring and integrating businesses, combined with his expertise in the mental health sector make him uniquely positioned to contribute to Novamind’s strategic growth plans.”

Read More: https://agoracom.com/ir/Novamind/forums/discussion/topics/756466-novamind-expands-leadership-team-accelerating-m-a/messages/2306202#message

Ortho Regenerative Technologies $ORTH.ca $ORTIF Well-positioned for Next Phase of Development

Posted by AGORACOM at 3:43 PM on Tuesday, March 2nd, 2021
Ortho

MONTREAL , March 2, 2021 – Ortho Regenerative Technologies Inc . (CSE: ORTH) (OTCQB: ORTIF) (” Ortho RTI ” or the ” Company “), a clinical stage orthobiologics company focused on the development of novel soft tissue repair regenerative technologies, today provided a review of 2020 calendar year activities and a look forward at planned future milestones as the Company transitions from preclinical to clinical stage.

2020 Achievements

  • Completed four non-brokered private placements that raised an aggregate C$6.7 million . The company now has more than $2 million cash on hand to fund its regulatory and clinical stage projects through 2022.
  • In March and July, Ortho RTI announced positive preclinical results that confirmed the safety profile and demonstrated statistically significant improvement over standard of care for rotator cuff repair.
  • Following a request for designation to the FDA, ORTHO-R was classified in August as a drug/biologic, which management believes will enhance its long-term market potential.
  • In October, the Company appointed Mukesh Ahuja , MBBS, MSc as Vice-President Clinical and Medical Affairs, who brings extensive expertise in orthobiologics clinical development.
  • In October, Ortho RTI shares began trading on the OTCQB market, facilitating better access for US investors and improved trading liquidity.
  • In November, Ortho RTI initiated the scale-up and manufacturing of cGMP clinical trial material to be used in the upcoming ORTHO-R Phase I/II rotator cuff tear repair clinical trial in the US.

Read More: https://agoracom.com/ir/OrthoRegenerativeTechnologies/forums/discussion/topics/756371-ortho-regenerative-technologies-well-positioned-for-next-phase-of-development/messages/2306048#message

AI/ML’s $AIML.ca $FIRZF CEO Appointed to Advisory Board of ST Innovations $PFM.ca $DM.ca $ADK.ca

Posted by AGORACOM at 3:39 PM on Tuesday, March 2nd, 2021
AI/ML Innovations Inc.

TORONTO , March 2, 2021 – AI/ML Innovations Inc. (CSE: AIML), a company committed to acquiring and advancing Artificial Intelligence/Machine Learning technologies that address urgent societal needs, is pleased to announce that Randy Duguay, CEO of AI/ML Innovations Inc., was appointed to the University of Alberta’s ST Innovations Advisory Board in order to provide input and guidance regarding the commercialization of new technologies in the field of digital health innovations.

“The addition of Randy Duguay to this prestigious advisory board is mutually beneficial” said Tim Daniels , Executive Chairman of AI/ML Innovations Inc.

“Randy is able to share his wealth of expertise and experience in the field of digital health by mentoring and advising others, while simultaneously leveraging the human and technological resources of ST Innovations to the benefit of AI/ML Innovations.”

ST Innovations, the business arm of the University of Alberta’s SMART Network, is Alberta’s leading R&D services organization, connecting entrepreneurs with world-class researchers in support of the latest innovation and R&D.

Read More: https://agoracom.com/ir/AIMLInnovations/forums/discussion/topics/756368-ai-ml-s-ceo-appointed-to-advisory-board-of-st-innovations/messages/2306045#message

$HOLL Announces Closing of $7.9M Private Placement of Special Warrants, Including Full Exercise of Agents’ Option $CRON $GTBIF $INDS $META.ca $FAF.ca $WEED.ca

Posted by AGORACOM at 3:39 PM on Tuesday, March 2nd, 2021
Hollister Biosciences Inc. | CSE - Canadian Securities Exchange
  • The Company has now closed the brokered private placement of 21,635,094  Special Warrants and raised gross proceeds of $7,896,809.31

VANCOUVER, BC – March 2, 2021 – Hollister Biosciences Inc. (CSE:HOLL, OTC:HSTRF, FRANKFURT:HOB) (“Hollister” or the “Company”) is pleased to announce, further to its news releases of January 21, 2021, and January 20, 2021, that the Company has now closed the brokered private placement of 21,635,094  Special  Warrants of the  Company  (the  “Special  Warrants”)  at a  price of  $0.365  per  Special  Warrant and raised gross proceeds of $7,896,809.31 (the “Offering”), including 3,825,094 Special Warrants sold pursuant to the exercise in full of the agents’ option granted to the Agents (as defined herein).

Eight Capital acted as sole bookrunner and lead agent on behalf of a syndicate of agents including Haywood Securities Inc. and Paradigm Capital Inc. (together with Eight Capital, the “Agents”) under the Offering.

Each Special Warrant will be automatically exercisable into units of the Company (the “Units”), as described below. Each Unit consists of one common share of the Company (a “Share”) and one-half of one common share purchase warrant (each full warrant, a “Warrant”). Each Warrant will entitle the holder thereof to acquire one Share at a price of $0.50 per Share on or before January 2, 2025, being 46 months following the date of closing of the Offering (the “Closing Date”).

Each Special Warrant will be automatically exercisable, for no additional consideration, into Units on the date (the “Automatic Exercise Date”) that is the earlier of: (i) the date that is three business days following the date on which the Company either (A) obtains a receipt from the applicable securities regulatory authorities (the “Securities Commissions”) for a (final) short form prospectus qualifying distribution of the Units underlying the Special Warrants (the “Qualifying Prospectus”); or (B) files a supplement to a (final) short form base shelf prospectus qualifying the distribution of the Units underlying the Special Warrants (the “Qualifying Supplement”), and (ii) July 3, 2021, being the date that is four months and one day after the closing of the Offering.

Notwithstanding the foregoing, in the event the Company has not received a receipt from the Securities Commissions for the Qualifying Prospectus or filed a Qualifying Supplement on or before March 12, 2021, each holder of Special Warrants shall thereafter be entitled to acquire an additional one-half of one (0.5) Warrant for each Unit to be issued to such holder upon the automatic exercise of the Special Warrants, such that each Unit shall be comprised of one Share and one whole Warrant (collectively, the “Penalty Warrants”), without further payment or action on the part of the holder.

In connection with the Offering, the Company paid the Agents $651,084.20 in commissions and advisory fees and issued 1,441,580 special broker warrants (the “Special Broker Warrants”) to the Agents. Each Special Broker Warrant is automatically exercisable into one broker warrant (a “Broker Warrant”) for no additional payment on the Automatic Exercise Date. Each Broker Warrant will be exercisable into one Unit, subject to adjustment, at $0.365 per Unit for a period of 24 months from the closing of the Offering. Each Unit is comprised of one Share and one-half of one Warrant.

All securities issued in connection with the Offering are subject to a statutory hold period of four months plus a day in accordance with applicable securities legislation ending on July 3, 2021. The net proceeds received from the Offering will be used for working capital and general corporate purposes.

Read more HERE.

Red Light Holland $TRIP.ca $TRUFF Talks Up New Wisdom Truffle Design $RVV.ca $PSYC $FTRP $BUZZ

Posted by AGORACOM at 1:46 PM on Tuesday, March 2nd, 2021
https://i.ibb.co/ZdKv64V/Red-Light-Holland-Square.jpg
  • RED LIGHT HOLLAND LAUNCHES NEW LOGO AND INTERACTIVE WISDOM TRUFFLE COMPANION CREATED BY INTERNATIONALLY RENOWNED & AWARD-WINNING DESIGNER KARIM RASHID

Red Light Holland Corp. has revealed the company’s interactive Wisdom Truffle and new logo carefully and creatively designed by renowned designer and head of design for Red Light Holland, Karim Rashid.

The Wisdom Truffle will be produced in three different models which is expected to be sold across the world in Q4 2021, and it will be able to be pre-ordered on the Company’s website by the end of March 2021. Each model will support a different aspect of Red Light Holland’s iMicro healthy lifestyle and work in conjunction with Red Light Holland’s iMicro Journal WebApp (currently in use) and the Company’s completed immersive AR/VR apps.

“While focusing on our core business, our goal is also to create alternative revenue streams while building a global brand that is electric, alive and genuinely connects – which then encourages a lifestyle of healthy daily habits, including disconnecting from technology and reconnecting with nature and ourselves for mental clarity,” said Red Light Holland CEO and Director Todd Shapiro. “I’m amazed to be part of such a creative team that is combining Karim Rashid’s designs and Radix Motion’s technology. Together we are kicking ass with this unique combination of tech meeting real life through creative minds from all sides.

The Red Light Holland team is proud to help you see things differently.”Wisdom Truffle Companion Image 3

https://orders.newsfilecorp.com/files/2017/75834_8f45f1f054cfcac8_002full.jpg

“The design of the Wisdom Truffle companion promotes positivity and provides comfort. The Wisdom Truffle is also an incredible art piece that’s a great conversation starter around finding a healthier balance with our use of technology. Something we need now more than ever,” said Karim Rashid. “The three model sizes will fit different, use cases and together can transform any environment, bringing light, music and interactivity. The new logo reflects the Wisdom Truffle becoming Red Light Holland’s brand ambassador and it truly represents all of us proudly.”

Read More:https://agoracom.com/ir/RedLightHolland/forums/discussion/topics/756386-red-light-holland-launches-new-logo-and-interactive-wisdom-truffle-companion-created-by-internationally-renowned-award-winning-designer-karim-rashid/messages/2306069#message